NESS ZIONA, Israel, April 12,
2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company
utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"),
announced the appointment of Revital Mandil-Levin, PhD, MBA as Chief Business Development Officer, effective immediately. In this
position, Dr. Mandil-Levin will be responsible for business development initiatives aimed at leveraging the Company's rhCollagen
technology into new and emerging fields such as BioInk for 3D bioprinting of tissues and organs and aesthetics medicine, as well
as expanding the reach of the Company's marketed products, VergenixFG and VergenixSTR in existing and new territories.
Yehiel Tal, CEO of CollPlant: "We are pleased to welcome Revital to our leadership team in
these exciting times at Collplant. Revital has extensive experience in corporate business development, portfolio optimization and
strategic planning. Her impressive track record of executing business development programs, combined with her deep
understanding of the regenerative medicine field, will be valuable to our efforts to realize the potential of our rhCollagen
technology".
Revital Mandil-Levin, PhD, MBA has more than 15 years' experience in biotech startups and product development in the
pharmaceutical industry. Before joining CollPlant, from January 2014 to February 2018, Dr. Mandil-Levin served as Vice President Business Development at NeuroDerm Ltd (NASDAQ: NDRM),
a clinical-stage pharmaceutical company developing next-generation treatments for CNS disorders, where she had a major role in
the acquisition of NeuroDerm by Mitsubishi Tanabe Pharma Corporation for $1.1billion. From 2004 to
2013, Dr. Mandil-Levin served as Vice President Business Development at HealOr Ltd, a clinical-stage biopharmaceutical company
that developed novel drugs for skin regeneration in hard to heal wounds and dermatological diseases. Prior to that she served as
Business Development Manager at Proteologics Ltd. Dr. Mandil-Levin holds a PhD in Biochemistry from Bar-Ilan
University, Israel and an MBA from the Israeli College of Management School of
Business.
About CollPlant
CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs, and on developing and
commercializing tissue repair products for orthobiologics, and advanced wound care markets. Our products are based on our
rhCollagen (recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering
technology.
Our products address indications for diverse fields of organ and tissue repair and are ushering in a new era in regenerative
medicine. Our flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs, and our unique Vergenix
line of rhCollagen products includes a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote a
rapid optimal healing of acute and chronic wounds.
Safe Harbor Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to,
statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that
address activities, events or developments that Collplant intends, expects, projects, believes or anticipates will or may occur
in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates,"
"should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and
are based on assumptions and assessments made in light of management's experience and perception of historical trends, current
conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not
guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially
from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ
materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the
following: the Company's history of significant losses and its need to raise additional capital and its inability to obtain
additional capital on acceptable terms, or at all; the Company's expectations regarding the timing and cost of commencing
clinical trials with respect to tissues and organs which are based on its rhCollagen based Bioink, VergenixSTR, and VergenixFG;
the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen
based BioInk, VergenixSTR, and VergenixFG including but not limited to acceptance of an application for marketing authorization,
review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success
and market acceptance of the Company's rhCollagen based BioInk, VergenixSTR, and VergenixFG; the Company's ability to establish
sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and
resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the
Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection we are
able to establish and maintain for intellectual property rights and the Company's ability to operate its business without
infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new
technologies; general market, political, and economic conditions in the countries in which the Company operates; projected
capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. More detailed
information about the risks and uncertainties affecting Collplant is contained under the heading "Risk Factors" included in
CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that Collplant has made and may make
with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press
release and reflect CollPlant's current views with respect to future events, and Collplant does not undertake and specifically
disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise.
For more information about CollPlant, visit http://www.collplant.com
View original content with multimedia:http://www.prnewswire.com/news-releases/collplant-appoints-revital-mandil-levin-as-chief-business-development-officer-300628840.html
SOURCE CollPlant